Publications in collaboration with researchers from Hospital Universitario 12 de Octubre (16)

2022

  1. Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases

    Cancers, Vol. 14, Núm. 5

2021

  1. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

    Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888

  2. Tumor mutational burden assessment in non-small-cell lung cancer samples: Results from the TMB 2 harmonization project comparing three NGS panels

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 5

2019

  1. Clinical challenges and implications of intratumor heterogeneity

    Revista Espanola de Patologia, Vol. 52, Núm. 4, pp. 234-241

2017

  1. 18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: A window-of-opportunity randomized trial

    Clinical Cancer Research, Vol. 23, Núm. 6, pp. 1432-1441

  2. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer

    JAMA oncology, Vol. 3, Núm. 12, pp. e173290

  3. Treating KRAS -mutant NSCLC: Latest evidence and clinical consequences

    Therapeutic Advances in Medical Oncology, Vol. 9, Núm. 9, pp. 589-597

2016

  1. Autoregulatory loop of nuclear corepressor 1 expression controls invasion, tumor growth, and metastasis

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 113, Núm. 3, pp. E328-E337

2013

  1. DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: Implications for outcomes and histologic classification

    Carcinogenesis, Vol. 34, Núm. 5, pp. 1031-1038

  2. DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas

    British Journal of Cancer, Vol. 108, Núm. 8, pp. 1732-1742

2012

  1. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection

    Journal of Pathology, Vol. 227, Núm. 1, pp. 42-52

2011

  1. Consenso de la Sociedad Española de Anatomía Patológica (SEAP) y de la Sociedad Española de Oncología Médica (SEOM) sobre la determinación de HER2 en el carcinoma gástrico

    Revista Espanola de Patologia, Vol. 44, Núm. 1, pp. 32-48

2009

  1. Guidelines for HER2 testing in breast cancer. A national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Revista Espanola de Patologia, Vol. 42, Núm. 1, pp. 3-16

  2. Guidelines for HER2 testing in breast cancer: A national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 11, Núm. 6, pp. 363-375

2007

  1. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis

    Cancer Research, Vol. 67, Núm. 7, pp. 3450-3460

  2. Sox2: A possible driver of the basal-like phenotype in sporadic breast cancer

    Modern Pathology, Vol. 20, Núm. 4, pp. 474-481